In the following video, Motley Fool health-care analyst David Williamson discusses some very surprising trial results from Amgen (AMGN -0.88%). The company has announced phase 3 results that it has bioengineered a version of the herpes virus to attack melanoma, by singling out only fast-dividing cells. David tells us the possible ramifications both for investors and for patients.